Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 560.00
Bid: 558.00
Ask: 560.00
Change: -2.00 (-0.36%)
Spread: 2.00 (0.358%)
Open: 548.00
High: 562.00
Low: 548.00
Prev. Close: 562.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Update

3 Oct 2023 07:00

RNS Number : 4379O
Gooch & Housego PLC
03 October 2023
 

 

 

3 October 2023

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

Full Year Trading Update

and

Notice of Results

 

"Trading ahead of expectations. Integration of the two recent acquisitions progressing well"

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, announces that trading in the second half of the financial year has been strong, continuing the positive trends reported in its interim results. Revenues for the financial year have marginally exceeded market expectations.

 

Trading Update

 

Following the positive performance in the first half, the Group is pleased to report that trading momentum was sustained during the second half of the year.

 

In our Industrial markets volumes of our fibre and acousto optic assemblies used in advanced lithography systems grew more than offsetting the effects of some de-stocking by our customers in our industrial laser markets. Demand for our hi reliability fibre couplers used in subsea data cables has been stable and we expect demand to increase in the new financial year as our customers' new infrastructure projects are delivered.

 

In our A&D business we saw a number of fibre optic assembly programmes transition into full scale production. In the second half of the year, we made good progress on design and development activities for a number of customers for our embedded imaging periscope systems which has the potential to unlock significant orders based upon forecast vehicle build rates. In the commercial aerospace market there is sustained recovery in demand for our ring laser gyro components and we are steadily adding capacity to meet our customers' increased needs.

 

Revenues in the second half the year for our medical diagnostic devices grew thanks to deliveries for new customer programmes commencing. Our engineering team in Ashford is fully utilised supporting our customers new instrument development and qualification programmes.

 

In light of the positive trading performance in H2, enhanced by the focused operational improvements and capability investment over the last year, the Board expects the strong revenue performance to translate into a full year adjusted pre-tax profit above the current market expectations.

 

Acquisitions Update

The integration of GS Optics and Artemis into the G&H Group is proceeding to plan. Our ITL US business, focused on medical diagnostic devices, has now been relocated to GS Optics' facility in Rochester, NY and our expansion programme at that site is underway. We are adding new team members to our manufacturing and engineering teams there to support our US Life Sciences expansion plans as outlined in our new strategy.

The exploitation of commercial synergies between the newly acquired Artemis business and the rest of the G&H Group is already underway with a number of combined optical substrate and coating offerings now available to customers.

Cash

Cash generation in the second half of the financial year has been strong and allowing the Group to reduce its borrowing by $5.5m from its level immediately following the completion of the two acquisitions. Net debt (pre-IFRS 16) at the financial year end is, therefore, expected to be slightly better than market expectations.

Outlook

 

As at 30 September 2023 the Group's order book stood at £124.9m (30 September 2022: £147.7 million and 31 March 2023: £124.4m). Following the normalisation of the order book in the first half of the financial year there was a small order book decline in the second half of around 2.5% when measured on an organic, constant currency basis. Whilst destocking in some parts of our Industrial market is expected to impact in FY2024, especially in the first half, our A&D and Life Sciences revenues are both expected to grow. Around 75% of the order book is for delivery in FY2024 and this provides a good underpin for trading in the new financial year.

Notice of Results

The Company will announce its audited results for the year ended 30 September 2023 on 5 December 2023.

 

Charlie Peppiatt, Chief Executive Officer of Gooch and Housego, commented:

"I am delighted with the positive progress the Group has made in FY2023. Our operational performance has shown sustained improvement with on time delivery and lead times both improving significantly.

"The integration of GS Optics and Artemis into the G&H Group is on track. Both businesses are already benefitting from the additional market access and investment that being part of G&H brings.

"The detailed activities supporting the delivery of our recently announced strategic plan are now in place and support our budgeted plans for FY2024."

 

 

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / Sophie Wills / Abigail Gilchrist

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1.    Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2.    All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFSFFMEEDSEIS
Date   Source Headline
1st Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Jun 20202:53 pmRNSDirector/PDMR Shareholding
2nd Jun 202011:37 amRNSDirector/PDMR Shareholding
2nd Jun 20207:00 amRNSInterim Results
18th May 20207:00 amRNSNotification of Half Year Results
11th May 20207:00 amRNSAppointment of Non-Executive Director
23rd Apr 20204:23 pmRNSHolding(s) in Company
9th Apr 20203:25 pmRNSHolding(s) in Company
7th Apr 20207:00 amRNSHalf Year Trading Update
27th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20204:42 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSUS Facilities Update
17th Mar 20201:22 pmRNSFremont Facility Update
16th Mar 20201:56 pmRNSDirector/PDMR Shareholding
6th Mar 20209:45 amRNSDirector Share Purchase
3rd Mar 20207:00 amRNSStreamlining of Manufacturing
19th Feb 202012:23 pmRNSResult of AGM
19th Feb 20207:00 amRNSAGM Trading Update
3rd Feb 202012:08 pmRNSIssue of Equity and Total Voting Rights
14th Jan 202010:21 amRNSGrant of LTIP Awards
27th Dec 20193:26 pmRNSDirectorate: David Bauernfeind
11th Dec 20197:00 amRNSPosting of Annual Report and AGM Notice
9th Dec 20198:50 amRNSHolding(s) in Company
3rd Dec 20197:00 amRNSPreliminary Results
20th Nov 20198:42 amRNSBlock listing Interim Review
15th Nov 20194:41 pmRNSSecond Price Monitoring Extn
15th Nov 20194:35 pmRNSPrice Monitoring Extension
11th Nov 201911:18 amRNSConfirmation of Directorate Change
8th Nov 201912:54 pmRNSTotal Voting Rights
7th Oct 20197:00 amRNSFull Year Trading Update and Results Notification
6th Aug 201912:02 pmRNSPrice Monitoring Extension
18th Jul 201910:11 amRNSChief Financial Officer Appointment Timing Update
1st Jul 201910:57 amRNSDirector/PDMR Shareholding
6th Jun 201912:58 pmRNSDirector Share Purchase
4th Jun 20194:23 pmRNSDirectors' Share Purchases
4th Jun 20197:00 amRNSDirectorate Change
4th Jun 20197:00 amRNSInterim Results
28th May 20199:52 amRNSHolding(s) in Company
9th May 20197:00 amRNSNotification of Half Year Results
30th Apr 20197:00 amRNSAppointment of Chief Financial Officer
9th Apr 20197:00 amRNSCapital Markets Day
9th Apr 20197:00 amRNSHalf Year Trading Update
28th Mar 20195:28 pmRNSDirector/PDMR Shareholding
28th Mar 20195:25 pmRNSDirector/PDMR Shareholding
28th Mar 20195:24 pmRNSDirector/PDMR Shareholding
25th Mar 20195:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSITL signs manufacturing agreement with OrganOx
25th Feb 201911:27 amRNSDirector Share Purchase
21st Feb 20192:58 pmRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.